Thomas T.H. Chou

Partner | Hong Kong

tchou@mofo.com | 852 25850848

tchou@mofo.com
852 25850848

Successfully representing clients in various stages of business through their sophisticated cross-border financings, joint ventures, mergers, and acquisitions is highly rewarding.

中文 | English

Thomas has an active corporate practice, focusing on cross–border mergers and acquisitions (inbound and outbound), joint ventures as well as private equity and venture capital financings. His clients include emerging growth companies, as well as traditional and non–traditional investors (private equity and venture capital funds, family offices, corporate/strategic investment arms of corporations and financial institutions, and sovereign wealth funds.) His practice is focused on the technology, media and telecom, healthcare and life sciences, and consumer and retail industries.

Both clients and outside ranking entities routinely cite Thomas’ accomplishments: 

  • “Thomas has significant experience handling complex cross–border transactions across the Asia–Pacific region. His counsel is frequently sought by global technology corporations to advise on their investments in the region. He also commands considerable respect from private equity clients.”
  • “[He] is an adept practitioner with a range of expertise in venture capital and private equity mandates, including both early and late–stage investments and M&A, particularly in the technology sector.”
  • His clients pinpoint his “decades of venture capital experience both in the United States and in Asia,” with one noting: “He is patient, attentive to details and someone who has clearly conquered many battlefields.”
  • Thomas is particularly praised for his communications skills, with clients saying, “Any issues we had he would always provide a solution. He is not only interpreting regulations, but he is also commercially savvy.”

At MoFo, Thomas serves as co–head of our Asia Private Equity practice and a leader in our China M&A practice.

Show More

Experience

  • Represented SoftBank in its US$9.6 billion investment in Xiaoju Kuaizhi Inc. (DiDi), China’s leading ride–hailing and mobile transportation platform.

  • Represented Trusted Doctors (Xingren) in its strategic merger agreement with Tencent Doctorwork. The newly formed venture, which is named Tencent Trusted Doctors, will offer an ecosystem of both online and offline services devoted to leveraging Internet technology to provide high–quality and accessible healthcare service to customers all over the country.

  • Represented Oriente in its US$105 million initial funding round. The deal is reported to be one of the largest initial funding rounds by any startup in Asia and also for a FinTech company worldwide.

  • Represented Ally Bridge Group in connection with its investments in various life sciences companies, including 1) equity investment in Grail, Inc., a company developing a blood test to detect cancer before symptoms appear in order to offer higher survival rates compared to late–stage diagnosis; 2) Series G–1 round financing of PulmonX, a company based in California and focused on developing and marketing minimally–invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders.

  • Represented Happiness Capital as one of the investors in the $125 million Series C financing in Ÿnsect, French ag–tech innovator that specializes in breeding insects and transforming them into premium ingredients for fish feed, pet food, and organic plant fertilizers.

  • Represented a leading Chinese internet services company in multiple equity financings of a joint venture which offers a one–stop investment and wealth management platform for Chinese around the world. The JV company was licensed for asset management and securities advisory by the Hong Kong’s SFC.

  • Represented Asteri Networks in its initial convertible note financings from Asia–based investors.

  • Represented CLSA and a consortium of investors in relation to the Series C round investment into the ACT Genomics Group. Based in Taiwan, and with operations across Asia (Singapore, Japan, Hong Kong, PRC), ACT Genomics provides genomic profiling assays, molecular information to physicians and biopharmaceutical clients, and cancer treatment plans, cancer relapse, and drug resistance monitoring, as well as cancer risk assessment and immunotherapy evaluation.

  • Representing Airbnb on its China market entry.

  • Representing Kirin Holdings Company, a leading Japanese company in the global food and beverage market, in its equity investment for a 24.5% stake Brooklyn Brewing Corporation, a craft beer manufacturer in Brooklyn, New York.

  • Represented ClearVue Partners in a debt and minority equity investment in CHIC Fresh, a High Pressure Processing (HPP) juice and beverage company with operations in Asia, Europe, and North America.

  • Acts as general corporate counsel to Contineo Limited and advises the company in relation to corporate finance matters. Based in Hong Kong, Contineo operates a messaging network for equity–linked structured products with Barclays, BNP Paribas, BSI, Goldman Sachs, HSBC, JP Morgan, Julius Baer, Natixis, and Societe Generale as subscribers.

  • Represented Particle Inc., a leading media company that provides an intelligent news aggregator mobile application in China in its Series D financing with leading private equity investors and Chinese mobile handset companies.

  • Represented Spacious, an Asian online residential real estate marketplace, in its convertible note and Series A financing.

  • Represented Arocrest Capital Management in its Series B investment in TruTag Technologies, Inc., a provider of custom product authentication and brand protection solutions.

  • Represented GREE, Inc. in connection with HotelQuickly Holding’s Series A–1 equity financing. HotelQuickly is an Asia–Pacific–based technology firm enabling users throughout Asia to make last–minute hotel room bookings at deep discounted prices via mobile app. GREE was the lead investor in the Series A–1 round and was joined by the founder and chairman of Minor International, a Thailand based conglomerate in the hospitality space.

  • Represented JimuBox, a Beijing–based peer–to–peer (P2P) online lending platform, in its initial round of external financing.

  • Advising Kirin Holdings, a leading Japanese company in the global food and beverage market, in its US$400 million strategic joint venture with China Resources Enterprise, a Hong Kong–based consumer goods company operating in the retail, beer, food, and beverage markets throughout China.

  • Advised Rakuten, with respect to its joint venture with Baidu, Inc., the leading Chinese language Internet service provider, to build an online shopping mall for Chinese Internet users.

  • Advised one of the largest pharmaceutical companies in China, Harbin Pharmaceutical, in its asset acquisition of Pfizer’s swine vaccine business in China. This is the first MOFCOM–ordered divestment of its kind. Financial Times refers to this transaction as a “watershed Chinese deal…the first of many such transfers of western IP to Chinese groups arising from local competition rulings.”

  • Represented a major international investment banking firm’s private equity arm in an investment in a Hong Kong special purpose vehicle, which in turn acquired certain Philippine and other offshore entities that own and operate a polypropylene plant in The Philippines.

Show More


Close

Feedback

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.